Search for: "Takeda Pharmaceuticals International"
Results 21 - 40
of 69
Sort by Relevance
|
Sort by Date
19 Mar 2015, 5:00 am
Takeda Takeda Pharmaceutical Co., 737 F.3d 116 (1st Cir. 2013), which dismissed similar allegations, but not on their (lack of) substantive merit.Briefly, in D’Agostino, the attack was on the “narrow” indication for which the defendant had obtained FDA approval of its product:In broad terms, [relator] alleges that [defendant] misled the FDA during the . [read post]
3 Sep 2014, 9:00 am
Takeda Pharmaceutical Company Limited 13-1236Issue: Whether the “freely given” standard for the amendment of pleading embodied in Federal Rule of Civil Procedure 15(a), and espoused in Foman v. [read post]
1 Sep 2014, 7:04 am
. * Letter from AmeriKat: Judge Koh declares Takeda takes it too far with Mylan Dexilant declaration: The AmeriKat is back with a case review of Takeda Pharmaceutical Co., Ltd. et al v Mylan Inc. et al (here). [read post]
4 Aug 2014, 11:57 am
Takeda Acted in Bad Faith Evidence presented during the Allen trial, included internal memos revealing that Takeda Pharmaceutical executives knew about the bladder cancer risks before Actos was even on the market. [read post]
15 Jun 2014, 6:18 pm
Legal Reasoning (Prost, Plager, Chen)BackgroundPrevacid® SoluTab™Takeda Pharmaceutical Company Limited [et al.] [read post]
3 May 2014, 8:56 am
Merrell Dow Pharmaceuticals, Inc., 89 F.3d 594, 596-98 (9th Cir. 1996) (affirming exclusion of Dr. [read post]
15 May 2013, 4:45 am
Bankosky worked for Takeda Pharmaceuticals International, Inc., first as a director of Global Licensing and Business Development and then as a senior director. [read post]
15 Feb 2013, 9:29 am
Cir. 2007)) (internal quotation marks omitted). [read post]
5 Jun 2012, 12:10 pm
In that case, Bankosky had been a director in the business development group at Takeda Pharmaceuticals International, Inc. [read post]
24 May 2012, 4:23 am
We (and a whole bunch of other lawyers) assume that Takeda Pharmaceuticals will argue that the statute of limitations began to run on June 15, 2011, when the FDA issued an updated warning that one year of Actos use increases the risk of bladder cancer by more than 40%. [read post]
9 Mar 2012, 10:54 am
Pradaxa (dabigatran etexilate), manufactured by Boehringer Ingelheim Pharmaceuticals, was supposed to be one of those replacements. [read post]
17 Feb 2012, 2:00 am
., where the issue was whether supplemental documents should be produced to comply with post-trial determination pursuant to DGCL Section 220 that books and records must be provided. 2) DealBook: Kodak Can Remove Name From Oscar Venue, Judge Rules – This post shares how lawyers for Eastman Kodak won bankruptcy court permission on Wednesday to cancel the company’s sponsorship agreement with the Los Angeles theater where the Oscars have been held for the last 10 years, in an attempt… [read post]
16 Feb 2012, 6:00 am
A former employee of Takeda Pharmaceuticals International, Inc. has been charged after trading on inside information about the Japanese firm’s business alliances and corporate acquisitions. [read post]
9 Feb 2012, 12:50 pm
The SEC charged a former employee of Takeda Pharmaceuticals International, Inc. with trading on inside information about the Japanese firm’s business alliances and corporate acquisitions. [read post]
11 Jan 2012, 9:44 pm
Takeda International is a global pharmaceutical company headquartered in Japan. [read post]
27 Oct 2011, 4:24 am
The Actos plaintiffs allege that Takeda failed to warn about an increased risk of bladder cancer. [read post]
17 Sep 2011, 5:43 am
The lawsuit alleges that Actos' manufacturer, Takeda Pharmaceuticals North America (and other entities including: Takeda Global Research & Development Center Inc., Takeda Pharmaceuticals Company Ltd., Takeda Pharmaceuticals America, Takeda San Diego Inc., Takeda Pharmaceuticals International Inc and Eli Lilly and Company), was negligent for not providing any warnings regarding the increased… [read post]
18 Jul 2011, 8:21 am
Mylan, Takeda v. [read post]
18 Jul 2011, 8:21 am
Mylan, Takeda v. [read post]
31 May 2011, 8:38 pm
General WIPO SCP16: Joint proposal of the African Group and the Development Agenda Group on a work program on Patents and Health (Knowledge Ecology International) Rogue pharmacies slide under Google radar (IP Osgoode) Australia slips further out-of-step on pharmaceutical extensions (Patentology) EU: Proposed EU Customs Regulation may not dispel fear of wrongful drug seizures (IP Watch) EU: Karl De Gucht writes Andris Piebalgs on topic of European Union IPR demands on India and… [read post]
